

<b>Reference:</b>	FOI.9822.22
<b>Subject:</b>	Usage of intra-vitreous injections or implants
<b>Date of Request:</b>	8 September 2022

**Requested:**

Could you please tell me how many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2022:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab - Lucentis
- Ranibizumab - Ongavia

**Response:**

The table overleaf provides the number of each of the named intra-vitreous injections or implants administered by Hywel Dda University Health Board (UHB) between 1 May and 31 August 2022.

<b>Treatment</b>	<b>Number</b>
Aflibercept	2,432
Bevacizumab	0
Brolucizumab	1
Dexamethasone	34
Faricimab	0
Ranibizumab – Lucentis	1,613
Ranibizumab – Ongavia	0